Zoetis(US:ZTS)2026-02-12 21:49Financial Performance - Revenue for fiscal 2025 reached $9,467 million, representing a 2% increase from $9,256 million in 2024 and an 8% increase from $8,544 million in 2023[272] - Net income attributable to the company for fiscal 2025 was $2,673 million, an 8% increase from $2,486 million in 2024 and a 6% increase from $2,344 million in 2023[272] - Adjusted net income for fiscal 2025 was $2,847 million, up 6% from $2,693 million in 2024 and up 10% from $2,457 million in 2023[272] - Total revenue for 2025 was $9,467 million, an increase of $211 million or 2% compared to 2024, with operational revenue growth of $247 million or 3%[335] - Adjusted net income attributable to Zoetis for 2025 was $2,673 million, representing an 8% increase from $2,486 million in 2024[335] - Diluted earnings per share (EPS) for 2025 was $6.02, a 10% increase from $5.47 in 2024 and an 8% increase from $5.07 in 2023[383] Revenue Composition - Approximately 42% of the company's revenue for the year ended December 31, 2025, was denominated in foreign currencies, with 58% in U.S. dollars[288] - In 2025, the top two products, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributed approximately 16% and 12% of total revenue, respectively, with the top five products accounting for about 42% of total revenue[294] - The company's ten top-selling products and product lines contributed 57% of total revenue in 2025[294] - Companion animal products generated $6,587 million in revenue, a 5% increase from $6,278 million in 2024, while livestock products decreased by 5% to $2,764 million[337] - The U.S. revenue segment generated $5,097 million in 2025, remaining stable compared to $5,074 million in 2024, while international revenue was $4,254 million, up 4% from 2024[337] Expenses and Costs - Cost of sales decreased to $2,666 million in 2025, accounting for 28.2% of revenue, down from 29.4% in 2024[340] - Selling, general and administrative expenses rose to $2,378 million, a 3% increase from $2,318 million in 2024[342] - Research and development (R&D) expenses primarily focus on new product development and regulatory approvals, although specific figures are not disclosed[297] - Research and development expenses increased by $12 million or 2% to $698 million in 2025 compared to 2024[344] - Amortization of intangible assets decreased by $13 million or 9% to $128 million in 2025 compared to 2024[346] Taxation - The effective tax rate for 2025 was 20.4%, slightly up from 20.3% in 2024[335] - Provision for taxes on income increased to $687 million in 2025, an 8% rise from $637 million in 2024, with an effective tax rate of 20.4%[357][358] - The effective tax rate on adjusted pretax income was 20.3% in 2025, up from 19.8% in 2024, primarily due to a lower benefit related to foreign-derived intangible income[381] Cash Flow and Liquidity - Net cash provided by operating activities was $2,904 million in 2025, a decrease from $2,953 million in 2024, primarily due to timing of receipts and higher inventory build-up[401] - Cash and cash equivalents increased to $2,312 million in 2025 from $1,987 million in 2024, reflecting improved liquidity[405] - Working capital rose to $4,533 million in 2025, compared to $2,574 million in 2024, indicating stronger operational efficiency[405] - The ratio of current assets to current liabilities improved to 3.03:1 in 2025 from 1.75:1 in 2024, demonstrating enhanced liquidity position[405] Debt and Financing - The company completed a private offering of $2.0 billion convertible senior notes on December 18, 2025, with a maturity date of June 15, 2029[412] - The net proceeds from the convertible senior notes offering were $1,970 million, which were used for stock repurchases and capped call transactions[414] - The company issued $850 million of 4.150% senior notes due 2028 and $1.00 billion of 5.000% senior notes due 2035, with net proceeds used to redeem $600 million of 5.400% senior notes and $750 million of 4.500% senior notes[417] - The company has a share repurchase program authorized for up to $6 billion, with $3.2 billion spent to repurchase 23.9 million shares in 2025, leaving $2.4 billion remaining under this authorization[424] Market and Competitive Environment - The animal health industry is influenced by factors such as human population growth, increasing pet owners' commitment to animal health, and economic development in emerging markets[273][274] - The company faces competition from both established market participants and new entrants, with significant impacts from generic competition on certain products[277] - Sales of livestock products may be adversely affected by disease outbreaks, which can reduce demand for animal-derived food products[287] Strategic Focus - The company is focused on innovation across its diverse portfolio, including vaccines, pharmaceuticals, diagnostics, and genetics, to address unmet needs in animal health[284][292] - The company emphasizes the importance of digital solutions and data insights as core decision drivers for future growth in animal health[301] - Sustainability initiatives focus on improving access to care for animals and reducing environmental impact through innovative solutions[301] - The company aims to enhance customer experience by integrating its product portfolio and reducing engagement frictions[301] Risk Factors - The financial results are subject to variability due to factors such as global macroeconomic conditions, competitive dynamics, and supply chain disruptions[302] - Interest expense decreased by $3 million, or 1%, in 2025 compared to 2024, attributed to higher capitalized interest and gains on foreign exchange derivatives[354] - Other (income)/deductions—net showed a loss of $36 million in 2025, worsening from a loss of $19 million in 2024, mainly due to a net loss on the sale of certain product portfolios[355]